Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia

Treatment algorithms for severe aplastic anemia (SAA) are not well characterised for older patients. For older patients, treatment decisions are based not only on disease factors but also on their health and functional ability, in order to reduce the risk of treatment-related toxicity that may contribute to morbidity and mortality 1. For these reasons, HCT in older patients with SAA is usually only considered as second line treatment 2.

Source: Biology of Blood and Marrow Transplantation - September 4, 2018 Category: Hematology Authors: C. Rice, D.J. Eikema, J.C.W. Marsh, C. Knol, K. Hebert, H. Putter, E. Peterson, H.-J. Deeg, C.J.M. Halkes, J. Pidala, P. Anderlini, J. Tischer, N. Kroger, A. McDonald, J.H. Antin, N.P.M. Schaap, M. Hallek, H. Einsele, V. Mathews, N. Kapoor, J.J. Boelens, Source Type: research